We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To Buy […]
On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above. The panel also recommended RSV immunization for adults aged 60-74 years who are at increased risk for severe RSV disease, meaning they have certain chronic medical conditions. The recommendation is for adults who did not get an RSV vaccine last year. The RSV v
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines. In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged